ArticleFrontiers in genetics2026
Integrative bioinformatics screening of a M2 macrophage-associated gene signature for osimertinib resistance.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) Osimertinib is widely used in lung adenocarcinoma (LUAD), acquired resistance to this agent remains a major clinical challenge perplexing the academic community. While the genomic drivers of osimertinib resistance (OR) have been relatively well characterized, the non-genetic contributions of the tumor microenvironment (TME), especially the role of macrophage-mediated remodeling remains incompletely understood. Methods: To address this gap, a total of 6 lung cancer tissue samples were collected from a cohort of 6 NSCLC patients and subjected to single-cell RNA sequencing (scRNA-seq). Weighted gene co-expression network analysis (WGCNA) was performed on Gene Expression Omnibus (GEO) data to screen out OR-associated gene modules. The intersection of scRNA-seq-derived differentially expressed genes (DEGs) and module genes was used to identify M2 macrophage- and OR-related DEGs (MORGs). An ensemble machine learning framework encompassing 112 algorithm combinations was applied to construct a gene signature. Survival analysis was conducted in the EGFR-mutant TCGA cohort. In vitro cell experiments were further performed for functional validation. Results: Single-cell RNA sequencing firstly revealed an increased proportion of M2 macrophages in the OR group, and M2 macrophage-specific DEGs were identified between OR and non-OR groups. A total of seven MORGs were obtained by intersecting DEGs and OR-related module genes. A 7-gene signature was successfully established via machine learning. Survival analysis demonstrated that RRBP1 showed the strongest association with overall survival and was selected for further investigation. In vitro experiments confirmed that RRBP1 was significantly upregulated in the H1975OR cells. Knockdown of RRBP1 reduced cell viability and migration, lowered the IC50 of osimertinib, and increased the expression of ER stress markers such as GRP78 and CHOP. Conclusion: In summary, our study identified a 7-MORGs signature for OR, among which RRBP1 may be a candidate regulator for OR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.